Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.56 |
| ▸ | IDH1 | O75874 | 2/20 | 0.42 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 2/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13300282 | 0.96 | GSK3B (0.52) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL3104815 | 0.96 | GSK3B (0.52) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL3104739 | 0.88 | GSK3B (0.53) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL13300309 | 0.87 | GSK3B (0.52) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL13300243 | 0.87 | GSK3B (0.56) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL13300067 | 0.86 | GSK3B (0.59) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL13300281 | 0.83 | GSK3B (0.53) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL13300276 | 0.83 | GSK3B (0.51) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL3257404 | 0.83 | GSK3B (0.53) | GSK3BCCNB2CDK1CCNB1RPS6KB1 | |
| SCHEMBL13300094 | 0.81 | CRHR1 (0.37) | GSK3BCCNB2CDK1CCNB1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2198867-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | Vertex Pharmaceuticals, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-2198867-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | Vertex Pharmaceuticals, Inc. (US) | 2010-06-23 | — | — | EP | disclosed |
| EP-1474147-B1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1474147-B1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | VERTEX PHARMA (US) | 2010-05-05 | — | — | EP | disclosed |
| EP-1474147-A1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20030199526-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | VERTEX PHARMACEUTICALS, INCORPORATED | 2003-10-23 | — | — | US | disclosed |
| WO-2003049739-A1 | PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS | VERTEX PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199526-A1 | Pyrimidine-based compounds useful as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | GSK3B 1/4885CCNB2 555/4885CDK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.